Rosasea

01Pathophysiology

Rosacea is a chronic inflammatory dermatosis driven by dysregulation of the innate immune system, neurovascular hyperreactivity, and microbial colonization. Understanding these three pillars explains every clinical feature you will encounter in a vignette.

The central molecular pathway involves cathelicidin (LL-37), an antimicrobial peptide found in skin. In rosacea, the serine protease kallikrein 5 (KLK5) is abnormally upregulated, cleaving cathelicidin precursors into pro-inflammatory fragments that are structurally different from those in healthy skin. These aberrant LL-37 fragments promote vasodilation, leukocyte chemotaxis, and angiogenesis, which directly produces the persistent erythema and telangiectasias seen on exam. This is why the redness in rosacea is not simply "blushing" but rather a structural vascular remodeling process.

The neurovascular component explains the hallmark flushing episodes. Transient receptor potential vanilloid (TRPV) channels, particularly TRPV1 and TRPV2, are overexpressed on sensory neurons and vascular smooth muscle in affected skin. These channels are activated by heat, capsaicin (spicy food), alcohol, and UV radiation, causing exaggerated vasodilation. This is why patients can reliably name their triggers, and why the vignette may describe flushing after a glass of wine or sun exposure.

Demodex folliculorum mites are found in significantly higher density on rosacea-affected skin compared to normal controls. While Demodex itself is a normal commensal, its overgrowth and the bacteria it carries (particularly Bacillus oleronius) activate Toll-like receptor 2 (TLR2) on keratinocytes. TLR2 activation upregulates KLK5 expression, feeding back into the cathelicidin pathway and amplifying inflammation. This Demodex-TLR2-KLK5-cathelicidin axis explains why topical ivermectin (an anti-parasitic) is effective treatment: reducing mite burden breaks the inflammatory amplification loop.

Matrix metalloproteinases (MMPs), especially MMP-1, MMP-3, and MMP-9, are upregulated through this inflammatory cascade. They degrade extracellular matrix components, leading to progressive dermal connective tissue damage, permanent telangiectasias, and in the most severe form, tissue fibrosis and sebaceous gland hypertrophy that produces rhinophyma. This is why phymatous changes represent end-stage disease and are irreversible without surgical intervention.

02Classification and Clinical Manifestation

The current approach to rosacea uses phenotype-based classification rather than the older subtype system. However, exam vignettes still frequently reference the classic subtypes because they map neatly onto recognizable clinical presentations. You should know both frameworks.

Granulomatous rosacea is a distinct variant that may appear on exams. It presents with firm, non-tender, yellow-brown or red papules on the cheeks and periorificial area. Diascopy reveals an "apple-jelly" appearance. Biopsy shows non-caseating epithelioid granulomas, which places it in the differential of cutaneous sarcoidosis and lupus pernio.

03Diagnostic Workup

Rosacea is a clinical diagnosis. There is no single confirmatory laboratory test. The diagnostic criteria established by the National Rosacea Society Expert Committee identify persistent centrofacial erythema with periodic intensification as the single sufficient diagnostic feature. Two or more major features (flushing/transient erythema, papules/pustules, telangiectasias, ocular manifestations) can also establish the diagnosis.

The role of the workup is therefore not to "confirm rosacea" but to exclude dangerous look-alikes. The most important distinction is from systemic lupus erythematosus. When a vignette describes a malar rash and you are debating between rosacea and lupus, look for two clues: rosacea involves the nasolabial folds, while the classic lupus butterfly rash spares them; and rosacea lacks systemic features such as arthralgia, serositis, or cytopenias. If there is any doubt, ordering an ANA is the correct next step.

Biopsy is reserved for atypical presentations or when granulomatous disease is suspected. A vignette describing firm yellow-brown papules with an "apple-jelly" appearance on diascopy and non-caseating granulomas on histology should prompt you to consider granulomatous rosacea, but also place sarcoidosis and lupus vulgaris in the differential.

04Management and Treatment

All patients, regardless of subtype, should be counseled on trigger avoidance (UV protection with broad-spectrum SPF 30 or higher, avoiding alcohol, spicy food, extreme temperatures, and emotional stress) and use of gentle, non-irritating cleansers and moisturizers. This forms the foundation upon which pharmacologic therapy is built.

For mild papulopustular disease, topical monotherapy is the starting point. Topical ivermectin 1% cream applied once daily has demonstrated superiority over topical metronidazole in head-to-head trials and is often considered the preferred first-line topical agent. Its mechanism is twofold: it reduces Demodex mite density and has direct anti-inflammatory properties independent of its antiparasitic effect. Initial improvement is generally seen by 4 weeks, but a full 12- to 16-week course is needed before concluding treatment failure.

When topical therapy alone is insufficient, oral doxycycline at the 40 mg modified-release dose is added. This is a high-yield treatment concept: the sub-antimicrobial dose inhibits MMP activity (particularly MMP-9) and suppresses neutrophil chemotaxis without exerting antibiotic selective pressure. This makes it suitable for longer courses without promoting resistance.

Topical corticosteroids are contraindicated in rosacea. This is one of the most tested treatment pitfalls. Steroids may initially reduce erythema through vasoconstriction, but chronic use leads to worsening erythema, telangiectasia formation, and a flare known as steroid rosacea upon withdrawal. If a vignette describes a patient whose "rosacea improved with a cream but worsened when they stopped," think steroid-induced rosacea.

For pregnant patients, azelaic acid 15% gel is the safest topical option (FDA Category B). Doxycycline, minocycline, and isotretinoin are all contraindicated in pregnancy.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common trap with rosacea questions is misidentifying it as acne vulgaris. Both conditions present with facial papules and pustules, and a hurried test-taker may jump to "acne" without checking for comedones. The rule is absolute: no comedones means it is not acne. If a vignette describes a 40-year-old woman with papules and pustules on the cheeks and nose, persistent background erythema, and no mention of comedones, the answer is rosacea regardless of how "acne-like" the description sounds.

The second major trap involves topical corticosteroids. A vignette may describe a patient who was given a topical steroid for a "facial rash" and initially improved, only to develop worsening erythema, burning, and telangiectasias upon discontinuation. This is steroid-induced rosacea, and the correct answer is to discontinue the corticosteroid and initiate appropriate rosacea therapy. Never select "increase steroid potency" or "switch to a stronger corticosteroid" as the next step.

The third pearl is that ocular rosacea can present in isolation, without any cutaneous findings. A vignette describing recurrent blepharitis, meibomian gland dysfunction, or keratitis in a middle-aged patient, especially with a history of facial flushing, should raise suspicion for ocular rosacea even if the skin appears uninvolved at the time of presentation.

The fourth pearl involves the nasolabial fold rule for differentiating rosacea from lupus. This is a favorite discriminator on exams. When a vignette describes bilateral malar erythema, look at the nasolabial folds: involved means rosacea; spared means lupus. This single detail will often be the deciding clue in the stem.

Finally, remember that rhinophyma is not caused by alcohol use. This is a longstanding misconception. Rhinophyma is the end-stage phymatous manifestation of rosacea caused by sebaceous gland hyperplasia and dermal fibrosis. While alcohol can trigger flushing, it does not cause rhinophyma. If an answer choice attributes rhinophyma to "chronic alcoholism," it is a distractor.

The core competency being tested across rosacea questions is pattern recognition under ambiguity: distinguishing a disease defined by its clinical phenotype from mimickers that share overlapping features, and knowing the treatment contraindications (especially steroids) that function as decision traps in management questions.